13.96
+0.35(+2.57%)
Currency In USD
| Previous Close | 13.61 |
| Open | 14.3 |
| Day High | 14.8 |
| Day Low | 13.69 |
| 52-Week High | 76 |
| 52-Week Low | 4.56 |
| Volume | 58,657 |
| Average Volume | 1M |
| Market Cap | 63.12M |
| PE | -4.99 |
| EPS | -2.8 |
| Moving Average 50 Days | 15.35 |
| Moving Average 200 Days | 10.46 |
| Change | 0.35 |
If you invested $1000 in MiNK Therapeutics, Inc. (INKT) since IPO date, it would be worth $116.33 as of September 28, 2025 at a share price of $13.96. Whereas If you bought $1000 worth of MiNK Therapeutics, Inc. (INKT) shares 3 years ago, it would be worth $658.49 as of September 28, 2025 at a share price of $13.96.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
GlobeNewswire Inc.
Sep 25, 2025 11:30 AM GMT
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced that its President and Chief Executive Offi
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
GlobeNewswire Inc.
Sep 18, 2025 11:30 AM GMT
Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD)Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-st
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
GlobeNewswire Inc.
Aug 14, 2025 11:30 AM GMT
Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant awarded to launch AgenT-797 in GvHD clinical trial;